Contract development and manufacturing for early-stage drug programs
Quotient Sciences operates a vertically integrated CDMO spanning formulation development, clinical manufacturing, and trial execution across US and UK facilities. The tech stack centers on Salesforce, Veeva, and lab instrumentation (HPLC, LC-MS, ICP-MS), with emerging adoption of Python, SQL, and GCP—indicating early-stage automation and data infrastructure. Active hiring skews heavily toward research and manufacturing roles, aligned with their core service delivery, while LLM-based knowledge retrieval projects and AI/ML-driven drug development programs suggest internal tooling is beginning to shift toward computational support for manual-intensive processes.
Quotient Sciences is a contract development and manufacturing organization (CDMO) serving pharma companies in early and mid-stage drug development. The company provides integrated services spanning formulation optimization, Phase I–II clinical manufacturing under cGMP, translational pharmaceutics, and trial logistics. With over 1,300 staff across manufacturing and clinical facilities in the UK and US, Quotient operates at the contract end of the pharmaceutical supply chain—taking molecules from feasibility through clinical manufacturing. Current operational pain points center on eliminating silos across development workstreams, reducing cycle time and cost, and improving recruitment and proposal processes.
Salesforce, Veeva, LIMS, and lab instruments (HPLC, UPLC, LC-MS, ICP-MS). They also use Python, SQL, GCP, AWS, and Tableau for analytics and data work.
Yes. Active hiring includes 2 engineering roles, 3 data positions, and 17 research roles. Most openings are in manufacturing and research, with steady velocity across UK, US, and France.
Other companies in the same industry, closest in size